**Supplementary table S1**

**Table S1:** Patient’s treatment history and outcome, prior Cobomarsen clinical trial.

|  |  |  |  |
| --- | --- | --- | --- |
| **Treatment** | **Outcome-Complete Remission (CR)** | **Outcome-Relapse (R)** | **Enlargement****of lymph nodes** |
| R-CHOP**a** (6 cycles) | Clinical and radiographic R-CR1 after cycle 4 | After 14 months-R1 | right maxillary sinus mass and right axillary node |
| RICE**b** with intrathecal prophylaxis (2 cycles) | CR2 after cycle 2 | R2 | Right maxillary sinus mass |
| R-GemOx**c** (4 cycles) | CR3 | - | - |
| BEAM**d** conditioning with autologous stem cell rescue | CR4 | After 9 months-R3 | right neck node, and chest and bilateral inguinal nodes |
| Acalabrutinib (ACR-196) + ACP-319**e** | R-CR5 after 3 months | After 2 years-R4 | right neck node |

**a** R-CHOP: rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone.

**b** RICE: rituximab, ifosfamide, carboplatin and etoposide

**c**R-GemOx: rituximab, gemcitabine and oxaliplatin

**d**BEAM: carmustine etoposide, cytarabine and melphalan

**e**ACR-196 + ACP-319: inhibitor of Bruton tyrosine kinase (BTK) and phosphatidylinositol-3-kinase-delta inhibitor (PI3Kδ), respectively.

R-CR1: first radiographic-complete remission.

CR2: second complete remission.

R1: First relapse.